<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555697</url>
  </required_header>
  <id_info>
    <org_study_id>NIMH-R34-MH093453-NS</org_study_id>
    <nct_id>NCT01555697</nct_id>
  </id_info>
  <brief_title>Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia</brief_title>
  <acronym>Swerdlow-R34</acronym>
  <official_title>Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive training is moderately effective at reducing symptoms and improving life function&#xD;
      in schizophrenia patients. The present application develops a strategy for increasing the&#xD;
      effectiveness of cognitive training through the use of pro-cognitive medications. Specific&#xD;
      biomarkers will be studied that identify patients most sensitive to these pro-cognitive&#xD;
      medications, to test the feasibility of using these biomarkers in a large clinical trial of&#xD;
      medication-enhanced cognitive training in schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This R34 application responds to PAR-09-173, to achieve the first goal of this FOA by&#xD;
      supporting: &quot;the development and/or pilot testing of new or adapted interventions.&quot; The two&#xD;
      overarching goals of this application are: 1) to test the effects of the acute administration&#xD;
      of the NMDA antagonist, memantine (MEM), on sensorimotor gating and working memory (WM) in&#xD;
      schizophrenia (SZ) patients, and 2) to assess the feasibility of using MEM to predictably&#xD;
      enhance the therapeutic benefits of cognitive training in SZ.&#xD;
&#xD;
      The pharmacotherapy of SZ has been dominated by antidopaminergic drugs with limited clinical&#xD;
      impact. Some forms of psychosocial rehabilitation, such as cognitive training (CT), appear to&#xD;
      effectively reduce symptoms and improve function in SZ. The premise of this application is&#xD;
      that the benefits of CT in SZ might be enhanced by drugs that increase specific cognitive&#xD;
      abilities, including WM, even if these pro-cognitive drugs lack clinical impact when&#xD;
      administered without CT. The main goal of this application is to develop an innovative&#xD;
      intervention strategy that enhances the clinical benefits of CT in SZ through administration&#xD;
      of a pro-cognitive agent to biomarker-identified sensitive patients.&#xD;
&#xD;
      The investigators reported that a single dose of the widely used Alzheimer's disease&#xD;
      medication, MEM (20 mg p.o.), significantly increased prepulse inhibition (PPI) of the&#xD;
      startle reflex in healthy subjects. PPI-enhancing effects of MEM in healthy subjects are&#xD;
      associated with: 1) increased WM; and 2) phenotypes linked to the high activity Val158Met&#xD;
      COMT polymorphism. PPI is consistently impaired in SZ patients; lowest levels of PPI in&#xD;
      patients are associated with: 1) poor functional outcome; and 2) the Val/Val COMT genotype.&#xD;
      If our MEM findings in healthy subjects are reproduced in SZ patients, the investigators will&#xD;
      detect MEM-associated improvements in PPI and WM, particularly among Val/Val patients. The&#xD;
      investigators will then be positioned to test the hypothesis that acute PPI and WM-enhancing&#xD;
      effects of MEM predict therapeutic benefit of MEM in SZ patients undergoing CT.&#xD;
&#xD;
      This application has two aims: Aim 1 will assess the acute effects of MEM (0 vs. 10 or 0 vs.&#xD;
      20 mg p.o.) in 60 SZ patients, to test the prediction that MEM will increase PPI and enhance&#xD;
      WM in SZ patients, particularly in those characterized by low basal PPI levels and/or the&#xD;
      Val/Val COMT genotype. Mismatch negativity and gamma band synchronization will also be&#xD;
      assessed as potentially informative MEM-sensitive and functionally relevant biomarkers. Aim 2&#xD;
      will assess the feasibility of testing the therapeutic benefit of MEM as an adjunct to CT in&#xD;
      SZ patients, and the feasibility of testing the primary hypothesis that such benefit will be&#xD;
      predicted by increased PPI and/or WM in SZ patients after the Aim 1 single dose MEM&#xD;
      challenge. It is predicted that subject recruitment and completion in both arms of a&#xD;
      controlled 12-week CT trial in SZ out-patients among subjects completing Aim 1 will be&#xD;
      appropriate for testing both the overall effectiveness of MEM as an adjunct to CT and the&#xD;
      ability to predict this effectiveness among biomarker-identified patient subgroups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prepulse Inhibition</measure>
    <time_frame>approx 45 minutes</time_frame>
    <description>Prepulse inhibition of the startle reflex is the automatic reduction in startle magnitude (assessed here by EMG of orbicularis oculi) when a startling stimulus (here a 40 ms 118 dB(A) noise burst; &quot;PULSE&quot;) is preceded (here 10 - 120 msec) by a weak stimulus (here a 20 msec burst 16 dB over background &quot;PREPULSE&quot;). A %PPI metric is calculated based on the relative startle magnitude on (PREPULSE + PULSE) trials vs. PULSE alone trials. Possible maximal inhibition is 100%; there is no maximal &quot;negative&quot; value of inhibition. There is no clear &quot;advantage&quot; or &quot;disadvantage&quot; for lower or higher %PPI values, though on average, schizophrenia patients demonstrate lower % values compared to matched healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MATRICS</measure>
    <time_frame>approx 1 hour</time_frame>
    <description>MATRICS Consensus Cognitive Battery Performance: This is a standardized neurocognitive battery that assesses performance in 7 domains of neurocognition. Primary data are recorded based on normalized T-scores; a separate score is provided for each domain, and a Comprehensive score (Primary measure here) is also calculated across domains. Possible T-score range is 0 - 100; higher score reflects better performance.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Memantine/high</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>memantine 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/high</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator for memantine 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Memantine/low</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>memantine 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/low</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator for memantine 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.</description>
    <arm_group_label>Memantine/high</arm_group_label>
    <arm_group_label>Memantine/low</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.</description>
    <arm_group_label>Placebo/high</arm_group_label>
    <arm_group_label>Placebo/low</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of schizophrenia or schizoaffective disorder - depressed type&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age range,&#xD;
&#xD;
          -  Current alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <results_first_submitted>May 21, 2020</results_first_submitted>
  <results_first_submitted_qc>July 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2020</results_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Neal R. Swerdlow, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>prepulse inhibition</keyword>
  <keyword>neurocognition</keyword>
  <keyword>working memory</keyword>
  <keyword>memantine</keyword>
  <keyword>MATRICS Consensus Cognitive Battery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT01555697/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT01555697/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Schizophrenia: Placebo 1st, Then 10 mg Memantine</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 10 mg pill of memantine and is again tested in the laboratory.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Subjects: Placebo 1st, Then 10 mg Memantine</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participant in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 10 mg pill of memantine and is again tested in the laboratory.</description>
        </group>
        <group group_id="P3">
          <title>Subjects With Schizophrenia: 10 mg Memantine 1st, Then Placebo</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single 10 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
        </group>
        <group group_id="P4">
          <title>Healthy Subjects: 10 mg Memantine 1st, Then Placebo</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participants in this arm receive a single 10 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
        </group>
        <group group_id="P5">
          <title>Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 20 mg pill of memantine and is again tested in the laboratory.</description>
        </group>
        <group group_id="P6">
          <title>Healthy Subjects: Placebo 1st, Then 20 mg Memantine</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participant in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 20 mg pill of memantine and is again tested in the laboratory.</description>
        </group>
        <group group_id="P7">
          <title>Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single 20 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
        </group>
        <group group_id="P8">
          <title>Healthy Subjects: 20 mg Memantine 1st, Then Placebo</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participants in this arm receive a single 20 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Hours Lab Testing Day 1</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Approx 7 Day Washout</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Hours Lab Testing Day 2</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Schizophrenia: Placebo 1st, Then 10 mg Memantine</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 10 mg pill of memantine and is again tested in the laboratory.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Subjects: Placebo 1st, Then 10 mg Memantine</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participant in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 10 mg pill of memantine and is again tested in the laboratory.</description>
        </group>
        <group group_id="B3">
          <title>Subjects With Schizophrenia: 10 mg Memantine 1st, Then Placebo</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single 10 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
        </group>
        <group group_id="B4">
          <title>Healthy Subjects: 10 mg Memantine 1st, Then Placebo</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participants in this arm receive a single 10 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
        </group>
        <group group_id="B5">
          <title>Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 20 mg pill of memantine and is again tested in the laboratory.</description>
        </group>
        <group group_id="B6">
          <title>Healthy Subjects: Placebo 1st, Then 20 mg Memantine</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participant in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 20 mg pill of memantine and is again tested in the laboratory.</description>
        </group>
        <group group_id="B7">
          <title>Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single 20 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
        </group>
        <group group_id="B8">
          <title>Healthy Subjects: 20 mg Memantine 1st, Then Placebo</title>
          <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participants in this arm receive a single 20 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="10"/>
            <count group_id="B9" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" lower_limit="19" upper_limit="46"/>
                    <measurement group_id="B2" value="26.4" lower_limit="20" upper_limit="43"/>
                    <measurement group_id="B3" value="39.2" lower_limit="29" upper_limit="45"/>
                    <measurement group_id="B4" value="32.0" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="B5" value="38.9" lower_limit="28" upper_limit="48"/>
                    <measurement group_id="B6" value="29.6" lower_limit="21" upper_limit="36"/>
                    <measurement group_id="B7" value="35.7" lower_limit="21" upper_limit="48"/>
                    <measurement group_id="B8" value="23.8" lower_limit="19" upper_limit="32"/>
                    <measurement group_id="B9" value="32" lower_limit="19" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prepulse Inhibition</title>
        <description>Prepulse inhibition of the startle reflex is the automatic reduction in startle magnitude (assessed here by EMG of orbicularis oculi) when a startling stimulus (here a 40 ms 118 dB(A) noise burst; &quot;PULSE&quot;) is preceded (here 10 - 120 msec) by a weak stimulus (here a 20 msec burst 16 dB over background &quot;PREPULSE&quot;). A %PPI metric is calculated based on the relative startle magnitude on (PREPULSE + PULSE) trials vs. PULSE alone trials. Possible maximal inhibition is 100%; there is no maximal &quot;negative&quot; value of inhibition. There is no clear &quot;advantage&quot; or &quot;disadvantage&quot; for lower or higher %PPI values, though on average, schizophrenia patients demonstrate lower % values compared to matched healthy subjects.</description>
        <time_frame>approx 45 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Schizophrenia: Placebo 1st, Then 10 mg Memantine</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 10 mg pill of memantine and is again tested in the laboratory.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects: Placebo 1st, Then 10 mg Memantine</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participant in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 10 mg pill of memantine and is again tested in the laboratory.</description>
          </group>
          <group group_id="O3">
            <title>Subjects With Schizophrenia: 10 mg Memantine 1st, Then Placebo</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single 10 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects: 10 mg Memantine 1st, Then Placebo</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participants in this arm receive a single 10 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
          </group>
          <group group_id="O5">
            <title>Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 20 mg pill of memantine and is again tested in the laboratory.</description>
          </group>
          <group group_id="O6">
            <title>Healthy Subjects: Placebo 1st, Then 20 mg Memantine</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participant in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 20 mg pill of memantine and is again tested in the laboratory.</description>
          </group>
          <group group_id="O7">
            <title>Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single 20 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
          </group>
          <group group_id="O8">
            <title>Healthy Subjects: 20 mg Memantine 1st, Then Placebo</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participants in this arm receive a single 20 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
          </group>
        </group_list>
        <measure>
          <title>Prepulse Inhibition</title>
          <description>Prepulse inhibition of the startle reflex is the automatic reduction in startle magnitude (assessed here by EMG of orbicularis oculi) when a startling stimulus (here a 40 ms 118 dB(A) noise burst; &quot;PULSE&quot;) is preceded (here 10 - 120 msec) by a weak stimulus (here a 20 msec burst 16 dB over background &quot;PREPULSE&quot;). A %PPI metric is calculated based on the relative startle magnitude on (PREPULSE + PULSE) trials vs. PULSE alone trials. Possible maximal inhibition is 100%; there is no maximal &quot;negative&quot; value of inhibition. There is no clear &quot;advantage&quot; or &quot;disadvantage&quot; for lower or higher %PPI values, though on average, schizophrenia patients demonstrate lower % values compared to matched healthy subjects.</description>
          <units>% inhibition of startle</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="5.7"/>
                    <measurement group_id="O2" value="25.5" spread="8.1"/>
                    <measurement group_id="O3" value="23.7" spread="6.0"/>
                    <measurement group_id="O4" value="2.6" spread="19.2"/>
                    <measurement group_id="O5" value="-1.7" spread="9.9"/>
                    <measurement group_id="O6" value="-9.7" spread="33.2"/>
                    <measurement group_id="O7" value="34.2" spread="8.7"/>
                    <measurement group_id="O8" value="12.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memantine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="6.8"/>
                    <measurement group_id="O2" value="27.3" spread="6.5"/>
                    <measurement group_id="O3" value="-0.9" spread="13.7"/>
                    <measurement group_id="O4" value="31.1" spread="8.1"/>
                    <measurement group_id="O5" value="26.1" spread="7.8"/>
                    <measurement group_id="O6" value="29.9" spread="8.4"/>
                    <measurement group_id="O7" value="40.1" spread="7.1"/>
                    <measurement group_id="O8" value="14.6" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MATRICS</title>
        <description>MATRICS Consensus Cognitive Battery Performance: This is a standardized neurocognitive battery that assesses performance in 7 domains of neurocognition. Primary data are recorded based on normalized T-scores; a separate score is provided for each domain, and a Comprehensive score (Primary measure here) is also calculated across domains. Possible T-score range is 0 - 100; higher score reflects better performance.</description>
        <time_frame>approx 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Schizophrenia: Placebo 1st, Then 10 mg Memantine</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 10 mg pill of memantine and is again tested in the laboratory.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects: Placebo 1st, Then 10 mg Memantine</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participant in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 10 mg pill of memantine and is again tested in the laboratory.</description>
          </group>
          <group group_id="O3">
            <title>Subjects With Schizophrenia: 10 mg Memantine 1st, Then Placebo</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single 10 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects: 10 mg Memantine 1st, Then Placebo</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participants in this arm receive a single 10 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
          </group>
          <group group_id="O5">
            <title>Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 20 mg pill of memantine and is again tested in the laboratory.</description>
          </group>
          <group group_id="O6">
            <title>Healthy Subjects: Placebo 1st, Then 20 mg Memantine</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participant in this arm receive a single pill of placebo followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single 20 mg pill of memantine and is again tested in the laboratory.</description>
          </group>
          <group group_id="O7">
            <title>Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Schizophrenia subjects in this arm receive a single 20 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
          </group>
          <group group_id="O8">
            <title>Healthy Subjects: 20 mg Memantine 1st, Then Placebo</title>
            <description>This is a crossover design with 2 active doses used as between-subject factors. Healthy participants in this arm receive a single 20 mg pill of memantine followed by about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of placebo and is again tested in the laboratory.</description>
          </group>
        </group_list>
        <measure>
          <title>MATRICS</title>
          <description>MATRICS Consensus Cognitive Battery Performance: This is a standardized neurocognitive battery that assesses performance in 7 domains of neurocognition. Primary data are recorded based on normalized T-scores; a separate score is provided for each domain, and a Comprehensive score (Primary measure here) is also calculated across domains. Possible T-score range is 0 - 100; higher score reflects better performance.</description>
          <units>standardized T-score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="3.8"/>
                    <measurement group_id="O2" value="53.4" spread="2.3"/>
                    <measurement group_id="O3" value="41.1" spread="3.8"/>
                    <measurement group_id="O4" value="56.3" spread="2.4"/>
                    <measurement group_id="O5" value="34.2" spread="4.4"/>
                    <measurement group_id="O6" value="48.6" spread="4.3"/>
                    <measurement group_id="O7" value="37.7" spread="4.6"/>
                    <measurement group_id="O8" value="66.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memantine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="4.5"/>
                    <measurement group_id="O2" value="60.2" spread="2.7"/>
                    <measurement group_id="O3" value="34.3" spread="3.3"/>
                    <measurement group_id="O4" value="56.6" spread="6.6"/>
                    <measurement group_id="O5" value="35.8" spread="4.8"/>
                    <measurement group_id="O6" value="53.7" spread="5.8"/>
                    <measurement group_id="O7" value="31.0" spread="4.5"/>
                    <measurement group_id="O8" value="57.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Memantine</title>
          <description>Memantine: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neal Swerdlow, M.D., Ph.D.</name_or_title>
      <organization>UC San Diego</organization>
      <phone>619-543-6270</phone>
      <email>nswerdlow@health.ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

